Intermittent Cold Exposure and Brown Adipose Tissue Hyperplasia
NCT07048405
Recruiting
This clinical trial explores how repeated short-term cold exposure impacts the molecular and physiological function of brown adipose tissue (BAT), a thermogenic organ associated with improved cardiometabolic health. While intermittent cold exposure has been shown to increase BAT activity and mass, as measured by fluorodeoxyglucose (18F-FDG) uptake on positron emission tomography/computed tomography (PET/CT) scans, the molecular adaptations within BAT and other thermogenic tissues including skele... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
07/03/2025
Locations: Royal Infirmary of Edinburgh, Edinburgh, Not set
Conditions: Brown Adipose Tissue, Cold Exposure, 18F-FDG PET/CT
Register for Updates
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159
Recruiting
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Research Site, Birmingham, Alabama +60 locations
Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer
Register for Updates
Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry
NCT04907240
Recruiting
Collect real-world post-market clinical follow-up data on patients treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: iD3 Medical cvba, Berchem-Sainte-Agathe, Not set +26 locations
Conditions: Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms, Trauma Injury
Register for Updates
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219
Recruiting
The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvusertib monotherapy and combination therapy. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objectives of this study are to assess the effect of the treatment in terms of overall response, i.e. w... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +57 locations
Conditions: Ovarian Cancer
Register for Updates
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
NCT04360941
Recruiting
This clinical study is aiming to determine the safest doses and schedule for the combination of two drugs named palbociclib and avelumab. The study will also be investigating how effective the combination is for a subgroup of breast cancer patients whose cancer expresses the androgen receptor (AR) but not the oestrogen (hormone) or HER2 receptors. Palbociclib is a drug used in routine care for hormone-receptor (HR) positive and HER2 negative advanced breast cancer, the most common subtype of br... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: The Christie NHS Foundation Trust, Manchester, Greater Manchester +8 locations
Conditions: Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer
Register for Updates
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants
NCT07011511
Recruiting
This is a single-centre, participant- and investigator-blind, randomised, placebo controlled, single ascending dose study to assess the safety, tolerability and PK of a single dose of IM depot injection(s) of LAI formulations of MMV055 administered alone (Part A) and in combination with MMV371 (Part B) in healthy participants. It is planned to enroll up to 6 sequential cohorts of 8 healthy male participants and healthy female participants of non-childbearing potential in Part A. In Part B, up t... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/02/2025
Locations: Quotient Sciences, Nottingham, Not set
Conditions: Malaria, Falciparum
Register for Updates
Performance and Safety of LightForce® Therapy Lasers on Lateral Ankle Sprain
NCT06854016
Recruiting
DJO UK Ltd (ENOVIS) is conducting this study to assess the effectiveness of LightForce® Therapy Lasers on pain reduction in subjects with ankle soft tissue trauma and/or sport injury. In detail this study will assess superiority of LightForce® Therapy Lasers combined with standard of care, represented by RICE and physiotherapy/exercise program, compared to sham laser combined with standard of care (RICE and physiotherapy/exercise program) on pain reduction in subjects with acute grade I - II lat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Carioni Fisioterapia, Cassano D'adda, Milano +5 locations
Conditions: Ankle Sprain 1St Degree, Ankle Sprain 2Nd Degree, Acute Pain
Register for Updates
Performance and Safety of LightForce® Therapy Lasers on Shoulder Soft Tissue Inflammation Pain Reduction
NCT06759935
Recruiting
DJO UK Ltd (ENOVIS) is conducting this study to assess the effectiveness of LightForce® Therapy Lasers on pain reduction in shoulder soft tissue inflammation. In detail this study will assess superiority of LightForce® Therapy Lasers combined with standard of care, represented by physiotherapy/exercise program compared to sham laser combined with standard of care (physiotherapy/exercise program) on pain reduction in subjects with shoulder soft tissue inflammation due to Impingement (Subacromial... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Cabinet Attal, Serris, Not set +6 locations
Conditions: Shoulder Pain, Shoulder Impingement Syndrome, Rotator Cuff Tendinitis
Register for Updates
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT06247995
Recruiting
In the phase I part, to determine the recommended doses (RD) and dosing regimens of \[177Lu\]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor. In the phase II part, to evaluate the preliminary anti-tumor activity of two different doses/regimens of \[... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/02/2025
Locations: UCLA Medical Center, Los Angeles, California +29 locations
Conditions: Breast Cancer
Register for Updates
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT06669247
Recruiting
This study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined). This study is the first time REGN7945 will be tested in humans. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after several other therapies... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Illawarra Cancer Care Centre, Wollongong, New South Wales +6 locations
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
NCT06484868
Recruiting
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/02/2025
Locations: Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille, Not set +11 locations
Conditions: Partial Lipodystrophy
Register for Updates
Feasibility of a Tailored Online Self-compassion Intervention
NCT07051005
Recruiting
The goal of this clinical trial is to examine the feasibility and acceptability of an online programme that is based on Compassionate Mind Training (CMT) over four-weeks. The programme intends to share information and strategies to reduce diabetes distress, self-criticism, and shame, and improve physical health in people who have Type 1 and Type 2 Diabetes Mellitus.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/02/2025
Locations: Betsi Cadwaladr University Health Board (BCUHB), Bangor, Wales +1 locations
Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM)
Register for Updates